Clinical Trial Results:
A 48 week extension to CTBM100C2401, a single arm open-label, multicenter, phase IV trial, to assess long term safety of tobramycin inhalation powder (TIP) in patients with Cystic Fibrosis
Due to EudraCT system limitations, which EMA is aware of, data using 999 as data points in this record are not an accurate representation of the clinical trial results. Please use https://www.novctrd.com/CtrdWeb/home.novfor complete trial results.
|
Summary
|
|
EudraCT number |
2012-003532-23 |
Trial protocol |
HU ES IT DE |
Global end of trial date |
18 Nov 2014
|
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
07 Jul 2018
|
First version publication date |
07 Jul 2018
|
Other versions |
|
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
|
Trial identification
|
|||
Sponsor protocol code |
CTBM100C2401E1
|
||
|
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT01775137 | ||
WHO universal trial number (UTN) |
- | ||
|
Sponsors
|
|||
Sponsor organisation name |
Novartis Pharma AG
|
||
Sponsor organisation address |
CH-4002, Basel, Switzerland,
|
||
Public contact |
Novartis Pharma AG, Clinical Disclosure Office, +41 613241111,
|
||
Scientific contact |
Novartis Pharma AG, Clinical Disclosure Office, +41 613241111,
|
||
|
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
|
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
18 Nov 2014
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
18 Nov 2014
|
||
Was the trial ended prematurely? |
No
|
||
|
General information about the trial
|
|||
Main objective of the trial |
The main objective of the study was to assess the safety of tobramycin inhalation powder (TIP) with respect to incidence of treatment emergent adverse events (AEs) over 12 treatment cycles (6 treatment cycles in the core study and 6 treatment cycles in the extension study).
|
||
Protection of trial subjects |
The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Conference on Harmonization (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trial subjects were followed. Rescue medications like anti-pseudomonal antibiotics, macrolides (anti-inflammatory regimen), bronchodilators, inhaled hypertonic saline, inhaled corticosteroids were allowed for pulmonary exacerbations as per the discretion of the investigator. If the subject’s condition/disease required the medications which potentially affected the systemic tobramycin levels, inhalation of study medication was continued only at the investigator’s discretion. The investigator provided follow-up medical care for all subjects who were prematurely withdrawn from the study, or referred them for appropriate ongoing care.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
27 Feb 2013
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
|
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
United States: 6
|
||
Country: Number of subjects enrolled |
Canada: 1
|
||
Country: Number of subjects enrolled |
Mexico: 5
|
||
Country: Number of subjects enrolled |
Argentina: 9
|
||
Country: Number of subjects enrolled |
Australia: 5
|
||
Country: Number of subjects enrolled |
Spain: 6
|
||
Country: Number of subjects enrolled |
Germany: 5
|
||
Country: Number of subjects enrolled |
Hungary: 1
|
||
Country: Number of subjects enrolled |
Italy: 7
|
||
Worldwide total number of subjects |
45
|
||
EEA total number of subjects |
19
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
2
|
||
Adolescents (12-17 years) |
10
|
||
Adults (18-64 years) |
33
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
||
|
|||||||||||||||||||
|
Recruitment
|
|||||||||||||||||||
Recruitment details |
The study was conducted at 22 centres in 9 countries. | ||||||||||||||||||
|
Pre-assignment
|
|||||||||||||||||||
Screening details |
Of 96 subjects who completed the core study (CTBM100C2401), only 45 subjects were enrolled in the extension study. | ||||||||||||||||||
|
Period 1
|
|||||||||||||||||||
Period 1 title |
Overall study (overall period)
|
||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||
Allocation method |
Not applicable
|
||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||
Blinding implementation details |
As the study was an open-label study, this section was not applicable.
|
||||||||||||||||||
|
Arms
|
|||||||||||||||||||
|
Arm title
|
Tobramycin inhalation powder | ||||||||||||||||||
Arm description |
Subjects inhaled four capsules of tobramycin inhalation powder (28 mg) twice daily (bid) via the T326 inhaler device, for 28 days (treatment phase in each cycle). Each treatment phase therefore consisted of 112 mg tobramycin (4 capsules of 28 mg each) with the total daily dose of 224 mg tobramycin (112 mg bid). The treatment phase was followed by 28 days of no study treatment (off treatment in each cycle). These 56 days represented 1 cycle of therapy. | ||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||
Investigational medicinal product name |
Tobramycin
|
||||||||||||||||||
Investigational medicinal product code |
TBM100
|
||||||||||||||||||
Other name |
|||||||||||||||||||
Pharmaceutical forms |
Inhalation powder, hard capsule
|
||||||||||||||||||
Routes of administration |
Inhalation use
|
||||||||||||||||||
Dosage and administration details |
Four capsules of tobramycin inhalation powder (28 mg) bid via the T 326 inhaler device, for 28 days in each treatment phase.
|
||||||||||||||||||
|
|||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Baseline characteristics reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Tobramycin inhalation powder
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects inhaled four capsules of tobramycin inhalation powder (28 mg) twice daily (bid) via the T326 inhaler device, for 28 days (treatment phase in each cycle). Each treatment phase therefore consisted of 112 mg tobramycin (4 capsules of 28 mg each) with the total daily dose of 224 mg tobramycin (112 mg bid). The treatment phase was followed by 28 days of no study treatment (off treatment in each cycle). These 56 days represented 1 cycle of therapy. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||
|
End points reporting groups
|
|||
Reporting group title |
Tobramycin inhalation powder
|
||
Reporting group description |
Subjects inhaled four capsules of tobramycin inhalation powder (28 mg) twice daily (bid) via the T326 inhaler device, for 28 days (treatment phase in each cycle). Each treatment phase therefore consisted of 112 mg tobramycin (4 capsules of 28 mg each) with the total daily dose of 224 mg tobramycin (112 mg bid). The treatment phase was followed by 28 days of no study treatment (off treatment in each cycle). These 56 days represented 1 cycle of therapy. | ||
|
|||||||||||||||||||||||
End point title |
Number of subjects with adverse events (AEs), serious adverse events (SAEs), AEs/SAEs leading to discontinuation of study drug and deaths over 12 treatment cycles [1] | ||||||||||||||||||||||
End point description |
An AE was defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of study drug, whether or not related to study drug. A SAE was defined as an event which was fatal or life threatening, required or prolonged hospitalization, was significantly or permanently disabling or incapacitating, constituted a congenital anomaly or a birth defect, or encompassed any other clinically significant event that could jeopardize the subject or require medical or surgical intervention to prevent one of the aforementioned outcomes. Based on the severity, AEs were categorised into 3 types as mild, moderate and severe. Death was a fatal event leading to permanent cessations of all vital functions of the body. The analysis was performed in extension safety population, defined as all the subjects who entered the extension study and received at least one dose of study drug within the extension.
|
||||||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||||||
End point timeframe |
Baseline (start of study treatment in core study) to Day 673 (end of the extension study)
|
||||||||||||||||||||||
| Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Only descriptive summary statistics was planned for this outcome measure. |
|||||||||||||||||||||||
|
|||||||||||||||||||||||
| No statistical analyses for this end point | |||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||
End point title |
Relative change from baseline in forced expiratory volume in one second (FEV1) percent predicted over 12 treatment cycles | ||||||||||||||||||||||||||||||||||||||
End point description |
FEV1 was defined as the volume of air expired in 1 second. FEV1 was assessed as a pulmonary function by using spirometry tests in accordance with American Thoracic Society/European Respiratory Society (ATS/ERS) criteria. FEV1% predicted is a normalized value of FEV1 calculated using the Knudsen equation, based upon subject’s age, gender and height. Relative change in FEV1 % predicted from baseline to pre-dose day X = ((pre-dose day*FEV1% predicted – baseline FEV1% predicted) / baseline FEV1 % predicted) x 100. The analysis was performed in extension safety population, defined as all the subjects who entered the extension study and received at least one dose of study drug within the extension and had FEV1% values at both baseline and the post baseline time points. The 'n' signifies those subjects evaluable for this measure at specified time points for each group, respectively.
|
||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||||
End point timeframe |
Baseline (start of study treatment in core study), Day 29, Day 85, Day 141, Day 197, Day 253, Day 309, Day 337, Day 365, Day 421, Day 477, Day 533, Day 589, Day 645, 673 (end of the extension study)
|
||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||
| No statistical analyses for this end point | |||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||
End point title |
Absolute change from baseline in Pseudomonas aeruginosa sputum density over 12 treatment cycles | ||||||||||||||||||||||||||||||||||||||
End point description |
Microbiological data was collected to understand the direct impact of the drug on the pathogens. Sputum samples were cultured for the presence of three Pseudomonas aeruginosa (P. aeruginosa) biotypes measured were mucoid, dry and small colony variant. Absolute change was determined using the formula = (Post-baseline value- baseline value). If no P. aeruginosa was isolated for a visit, log10 colony forming units (CFU) was imputed with log10 (19) for all biotypes. The analysis was performed in extension safety population, who had P. aeruginosa sputum density values at both baseline and the given time point. The 'n' signifies those subjects evaluable for this measure at specified time points for each group, respectively.
|
||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||||
End point timeframe |
Baseline (start of study treatment in core study), Day 29, Day 85, Day 141, Day 197, Day 253, Day 309, Day 337, Day 365, Day 421, Day 477, Day 533, Day 589, Day 645, 673 (end of the extension study)
|
||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||
| No statistical analyses for this end point | |||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Change from baseline in Tobramycin minimum inhibitory concentration (MIC) 50 and MIC 90 values for Pseudomonas aeruginosa over 12 treatment cycles | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
MIC was defined as the lowest concentration of an antimicrobial agent required to inhibit the visible growth of a microorganism after overnight incubation. Tobramycin MIC 50 and MIC 90 values were defined as the lowest concentration of tobramycin required to inhibit 50% and 90%, respectively, of the P. aeruginosa strains tested (mucoid,dry and small colony variant biotypes). The analysis was performed in safety population, who had microbiological data at specified time points. The 'n' signifies those subjects evaluable for this measure at specified time points for each group, respectively.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Baseline (start of study treatment in core study), Day 29, Day 85, Day 141, Day 197, Day 253, Day 309, Day 337, Day 365, Day 421, Day 477, Day 533, Day 589, Day 645, 673 (end of the extension study)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| No statistical analyses for this end point | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||
End point title |
Percentage of subjects who used new anti-pseudomonal antibiotics over 12 treatment cycles | ||||||||
End point description |
The rate of anti-pseudomonal antibiotic use were determined from the collection of concomitant medication during the study. The analysis was performed in extension safety population.
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Baseline of core study, Day 673 (end of the extension study)
|
||||||||
|
|||||||||
| No statistical analyses for this end point | |||||||||
|
|||||||||||||||||
End point title |
Total number of days of new anti-pseudomonal antibiotics use over 12 treatment cycles | ||||||||||||||||
End point description |
The total number of days with usage of new anti-pseudomonal antibiotic were determined. The analysis was performed in extension safety population. The 'n' signifies those subjects evaluable for this measure at specified time points for each group, respectively.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Baseline of core study, Day 673 (end of the extension study)
|
||||||||||||||||
|
|||||||||||||||||
| No statistical analyses for this end point | |||||||||||||||||
|
|||||||||
End point title |
Time to use of new anti-pseudomonal antibiotics over 12 treatment cycles | ||||||||
End point description |
Time to first usage of anti-pseudomonal antibiotic was determined using Kaplan Meier estimate. Subjects without an event were censored at the date of the last available post-baseline measurement. The analysis was performed in extension safety population.
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Baseline of core study, Day 673 (end of the extension study)
|
||||||||
|
|||||||||
| No statistical analyses for this end point | |||||||||
|
|||||||||
End point title |
Percentage of subjects hospitalized due to respiratory related serious adverse events (SAEs) over 12 treatment cycles | ||||||||
End point description |
The percentage of the subjects hospitalized due to serious respiratory-related AEs were determined during the study. The analysis was performed in extension safety population.
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Baseline of core study, Day 673 (end of the extension study)
|
||||||||
|
|||||||||
| No statistical analyses for this end point | |||||||||
|
|||||||||
End point title |
Number of hospitalization days due to respiratory related serious adverse events (SAEs) over 12 treatment cycles | ||||||||
End point description |
The total number of hospitalization days due to serious respiratory-related adverse events was analyzed using Kaplan-Meier estimate. The analysis was performed in extension safety population.
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Baseline of core study, Day 673 (end of the extension study)
|
||||||||
|
|||||||||
| No statistical analyses for this end point | |||||||||
|
|||||||||
End point title |
Time to first hospitalization due to respiratory related serious adverse events (SAEs) over 12 treatment cycles | ||||||||
End point description |
The day of first hospitalization due to serious respiratory-related adverse events was analyzed using Kaplan Meier estimate. The analysis was performed in extension safety population. Here, 99999.9 represents not estimable data due to an insufficient number of events.
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Baseline of core study, Day 673 (end of the extension study)
|
||||||||
|
|||||||||
| No statistical analyses for this end point | |||||||||
|
|||||||||||||||||||||||||||||||||||
End point title |
Acute relative change from pre-dose to 30-minute post-dose in forced expiratory volume in one second (FEV1) percent predicted over 12 treatment cycles | ||||||||||||||||||||||||||||||||||
End point description |
FEV1 was defined as the volume of air expired in 1 second. FEV1 was assessed as a pulmonary function by using spirometry tests in accordance with American Thoracic Society/European Respiratory Society (ATS/ERS) criteria. Relative change in FEV1 % predicted was calculated by using the formula = 100 * (30-min post-dose value - pre-dose value) / pre-dose value. The analysis was performed in extension safety population. The 'n' signifies those subjects evaluable for this measure at specified time points for each group, respectively
|
||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||
End point timeframe |
Baseline (start of study treatment in core study), Day 29, Day 85, Day 141, Day 197, Day 253, Day 309, Day 337, Day 365, Day 421, Day 477, Day 533, Day 589, Day 645, 673 (end of the extension study)
|
||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
| No statistical analyses for this end point | |||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||
End point title |
Relative change from baseline in forced expiratory volume in one second (FEV1) percent predicted over 6 treatment cycles in extension study | ||||||||||||||||||||||
End point description |
FEV1 was defined as the volume of air expired in 1 second. FEV1 was assessed as a pulmonary function by using spirometry tests in accordance with American Thoracic Society/European Respiratory Society (ATS/ERS) criteria. FEV1% predicted is a normalized value of FEV1 calculated using the Knudsen equation, based upon subject’s age, gender and height. Relative change in FEV1 % predicted from baseline to pre-dose day X = ((pre-dose day*FEV1% predicted – baseline FEV1% predicted) / baseline FEV1 % predicted) x 100. The analysis was performed in extension safety population, defined as all the subjects who entered the extension study and received at least one dose of study drug within the extension and had FEV1% values at both baseline and the post baseline time points. The 'n' signifies those subjects evaluable for this measure at specified time points for each group, respectively.
|
||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||
End point timeframe |
Baseline (start of study treatment in extension study), Day 365, Day 421, Day 477, Day 533, Day 589, Day 645, 673 (end of the extension study)
|
||||||||||||||||||||||
|
|||||||||||||||||||||||
| No statistical analyses for this end point | |||||||||||||||||||||||
|
|||||||||||||||||||||||
End point title |
Absolute change from baseline in Pseudomonas aeruginosa density over 6 treatment cycles in extension study | ||||||||||||||||||||||
End point description |
Microbiological data was collected to understand the direct impact of the drug on the pathogens. Sputum samples were cultured for the presence of three Pseudomonas aeruginosa (P. aeruginosa) biotypes measured were mucoid, dry and small colony variant. If no P. aeruginosa was isolated for a visit, log10 colony forming units (CFU) was imputed with log10 (19) for all biotypes. Absolute change was calculated by using the formula = (Value at actual time point - start of extension value). The analysis was performed in extension safety population, who had P. aeruginosa sputum density values at both baseline and the given time point. The 'n' signifies those subjects evaluable for this measure at specified time points for each group, respectively.
|
||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||
End point timeframe |
Baseline (start of study treatment in extension study), Day 365, Day 421, Day 477, Day 533, Day 589, Day 645, 673 (end of the extension study)
|
||||||||||||||||||||||
|
|||||||||||||||||||||||
| No statistical analyses for this end point | |||||||||||||||||||||||
|
|||||||||
End point title |
Percentage of subjects who used new anti-pseudomonal antibiotics in extension study | ||||||||
End point description |
The rate of anti-pseudomonal antibiotic use were determined from the collection of concomitant medication during the study. The analysis was performed in extension safety population.
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Baseline of extension study, Day 673 (end of extension study)
|
||||||||
|
|||||||||
| No statistical analyses for this end point | |||||||||
|
|||||||||||||||||
End point title |
Total number of days of new anti-pseudomonal antibiotics use in extension study | ||||||||||||||||
End point description |
The total number of days with usage of new anti-pseudomonal antibiotic were determined. The analysis was performed in extension safety population. The 'n' signifies those subjects evaluable for this measure at specified time points for each group, respectively.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Baseline of extension study, Day 673 (end of extension study)
|
||||||||||||||||
|
|||||||||||||||||
| No statistical analyses for this end point | |||||||||||||||||
|
|||||||||
End point title |
Time to use of new anti-pseudomonal antibiotics in extension study | ||||||||
End point description |
Time to first usage of anti-pseudomonal antibiotic was determined using Kaplan Meier estimate. Subjects without an event were censored at the date of the last available post-baseline measurement. The analysis was performed in extension safety population.
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Baseline of extension study, Day 673 (end of extension study)
|
||||||||
|
|||||||||
| No statistical analyses for this end point | |||||||||
|
|||||||||
End point title |
Percentage of subjects hospitalized due to respiratory related serious adverse events (SAEs) in extension study | ||||||||
End point description |
The percentage of the subjects hospitalized due to serious respiratory-related AEs were determined during the study. The analysis was performed in extension safety population.
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Baseline of extension study, Day 673 (end of extension study)
|
||||||||
|
|||||||||
| No statistical analyses for this end point | |||||||||
|
|||||||||
End point title |
Number of hospitalization days due to respiratory related serious adverse events (SAEs) in extension study | ||||||||
End point description |
The total number of hospitalization days due to serious respiratory-related adverse events was analyzed using Kaplan-Meier estimate. The analysis was performed in extension safety population.
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Baseline of extension study, Day 673 (end of extension study)
|
||||||||
|
|||||||||
| No statistical analyses for this end point | |||||||||
|
|||||||||
End point title |
Time to first hospitalization due to respiratory related serious adverse events (SAEs) in extension study | ||||||||
End point description |
The day of first hospitalization due to serious respiratory-related adverse events was analyzed using Kaplan Meier estimate. The analysis was performed in extension safety population.
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Baseline of extension study, Day 673 (end of extension study)
|
||||||||
|
|||||||||
| Notes [2] - End point is not estimeble due to low occurrences of the event |
|||||||||
| No statistical analyses for this end point | |||||||||
|
|||||||||||||||||
End point title |
Number of subjects with adverse events (AEs), serious adverse events (SAEs), AEs/SAEs leading to discontinuation of study drug and deaths over 6 treatment cycles in extension study | ||||||||||||||||
End point description |
An AE was defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of study drug, whether or not related to study drug. A SAE was defined as an event which was fatal or life threatening, required or prolonged hospitalization, was significantly or permanently disabling or incapacitating, constituted a congenital anomaly or a birth defect, or encompassed any other clinically significant event that could jeopardize the subject or require medical or surgical intervention to prevent one of the aforementioned outcomes. Death was a fatal event leading to permanent cessations of all vital functions of the body. The analysis was performed in extension safety population, defined as all the subjects who entered the extension study and received at least one dose of study drug within the extension.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Baseline (start of study treatment in extension study) to Day 673 (end of the extension study)
|
||||||||||||||||
|
|||||||||||||||||
| No statistical analyses for this end point | |||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Serious Adverse Events are monitored from date of First Subject First Visit (FSFV) until Last Subject Last Visit (LSLV). All other adverse events are monitored from First Subject First Treatment until Last Subject Last Visit.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
Consistent with EudraCT disclosure specifications, Novartis has reported under the Serious adverse events field “number of deaths resulting from adverse events” all those deaths, resulting from serious adverse events that are deemed to be causally related to treatment by the investigator.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
17.0
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Tobramycin inhalation powder
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects inhaled four capsules of tobramycin inhalation powder (28 mg) twice daily (bid) via the T326 inhaler device, for 28 days (treatment phase in each cycle). Each treatment phase therefore consisted of 112 mg tobramycin (4 capsules of 28 mg each) with the total daily dose of 224 mg tobramycin (112 mg bid). The treatment phase was followed by 28 days of no study treatment (off treatment in each cycle). These 56 days represented 1 cycle of therapy. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||
Substantial protocol amendments (globally) |
|||
| Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
| Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
| Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
| Due to EudraCT system limitations, which EMA is aware of, data using 999 as data points in this record are not an accurate representation of the clinical trial results. Please use https://www.novctrd.com/CtrdWeb/home.novfor complete trial results. | |||
